Fiche publication
Date publication
juillet 2022
Journal
Biomedicines
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENKIRANE-JESSEL Nadia
,
Pr FALCOZ Pierre-Emmanuel
,
Dr LINDNER Véronique
,
Pr OLLAND Anne
Tous les auteurs :
Lê H, Seitlinger J, Lindner V, Olland A, Falcoz PE, Benkirane-Jessel N, Quéméneur E
Lien Pubmed
Résumé
Synthetic 3D multicellular systems derived from patient tumors, or tumoroids, have been developed to complete the cancer research arsenal and overcome the limits of current preclinical models. They aim to represent the molecular and structural heterogeneity of the tumor micro-environment, and its complex network of interactions, with greater accuracy. They are more predictive of clinical outcomes, of adverse events, and of resistance mechanisms. Thus, they increase the success rate of drug development, and help clinicians in their decision-making process. Lung cancer remains amongst the deadliest of diseases, and still requires intensive research. In this review, we analyze the merits and drawbacks of the current preclinical models used in lung cancer research, and the position of tumoroids. The introduction of immune cells and healthy regulatory cells in autologous tumoroid models has enabled their application to most recent therapeutic concepts. The possibility of deriving tumoroids from primary tumors within reasonable time has opened a direct approach to patient-specific features, supporting their future role in precision medicine.
Mots clés
microfluidic, non-small-cell lung cancer, preclinical models, tumoroids
Référence
Biomedicines. 2022 07 12;10(7):
